Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298
Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer
Zhao Gao, Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Xiao-Yun Wang, Shi-Kai Wu, Xuan Jin
Zhao Gao, Xiao-Yun Wang, Shi-Kai Wu, Xuan Jin, Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China
Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Department of Pharmacy, Jilin Cancer Hospital, Changchun 130012, Jilin Province, China
Author contributions: Gao Z and Wang XY collected data; Gao Z and Wang XY wrote the manuscript; Gao Z, Shen ZG, Liu JH, Wang XY, and Wu SK analyzed the data; Wu SK and Jin X conceived of the review and edited the manuscript; and all authors read and approved the final manuscript.
Supported by the National High Level Hospital Clinical Research Funding (Multi-Center Clinical Research Project of Peking University First Hospital), No. 2022CR65.
Institutional review board statement: This study was approved by the Ethics Committee of Peking University First Hospital, approval No. 2025R0190-0001; and Jilin Cancer Hospital, approval No. 202501-003-01.
Informed consent statement: The informed consent was waived by the Institutional Review Board.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. jinxuanbdyy@outlook.com
Received: April 10, 2025
Revised: May 8, 2025
Accepted: June 11, 2025
Published online: June 28, 2025
Processing time: 77 Days and 14.1 Hours
Core Tip

Core Tip: Patients with microsatellite stable metastatic colorectal cancer typically exhibit an immunosuppressive tumor microenvironment and demonstrate a low response rate to immunotherapy. Clinical trial data suggest that chemotherapy and anti-angiogenic therapy may have the potential to enhance the response to immunotherapy in these patients. However, whether these research findings can be “replicated” in clinical practice still requires further validation through real-world studies. This study aims to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 immunotherapy as the first-line regimen for microsatellite stable metastatic colorectal cancer in the real world.